Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7229706 | 1.00 | POLB (0.42) | POLBALDH1A1TSHRLMNAKDM4E | |
| SCHEMBL10610305 | 0.83 | GPR119 (0.36) | ALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL7244851 | 0.81 | POLB (0.46) | POLBALDH1A1TSHRLMNAKMT2A | |
| SCHEMBL7250534 | 0.81 | POLB (0.46) | POLBALDH1A1TSHRLMNAKMT2A | |
| SCHEMBL9382586 | 0.80 | SMN1; SMN2 (0.41) | ALDH1A1TSHRLMNAKMT2ASMN1; SMN2 | |
| SCHEMBL642839 | 0.80 | SMN1; SMN2 (0.41) | ALDH1A1TSHRLMNAKMT2ASMN1; SMN2 | |
| SCHEMBL3674574 | 0.79 | USP30 (0.38) | — | |
| SCHEMBL7473661 | 0.79 | TSHR (0.45) | POLBALDH1A1TSHRLMNAKMT2A | |
| SCHEMBL7277310 | 0.79 | SLC7A5 (0.33) | KMT2AGAAMEN1 | |
| SCHEMBL7452676 | 0.79 | TSHR (0.45) | POLBALDH1A1TSHRLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10669242-B2 | Clostridium difficile toxin inhibitors | Venenum Biodesign, LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | Venenum Biodesign, LLC (US) | 2019-06-27 | — | — | US | disclosed |
| US-10150794-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-9902688-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| WO-2017214359-A1 | NOVEL CLOSTRIDIUM DIFFICILE TOXIN INHIBITORS | VENENUM BIODESIGN LLC (US) | 2017-12-14 | — | — | WO | disclosed |
| US-20170260230-A1 | COMPUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2017-09-14 | — | — | US | disclosed |
| EP-2623113-B1 | Compound for enzyme inhibition | ONYX THERAPEUTICS INC (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20160318852-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2016-11-03 | — | — | US | disclosed |
| WO-2016160677-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-9359375-B2 | Benzamides and nicotinamides as Syk modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| WO-2007056464-A1 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| WO-2007017510-A2 | ISOPHTHALIC ACID DIAMIDES FOR TREATING ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017511-A2 | COMPOUNDS FOR TREATING ALZHEIMER'S DISEASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | WO | disclosed |
| US-6626982-B1 | Adsorbing chemical samples onto inert carriers to form highly stable free-flowing solid for long term storage in, for example, a proprietary compound collection | ASTRAZENECA AB (SE) | 2003-09-30 | — | — | US | disclosed |
| US-6281235-B1 | CONTROL OF HYPERTENSION. | G.D. SEARLE & CO. | 2001-08-28 | — | — | US | disclosed |
| US-5849773-A | Amino acyl amino propargyl diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1998-12-15 | — | — | US | disclosed |
| US-5508295-A | RENIN INHIBITORS | G. D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5330996-A | Renin inhibitors | G. D. SEARLE & CO. (US) | 1994-07-19 | — | — | US | disclosed |
| WO-1993009108-A1 | AMINO ACYL AMINO PROPARGYL DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1993-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194147-A1 | Novel Clostridium Difficile Toxin Inhibitors | GABRA5, GABRA1, GABRA4 | POLB 4138/4885ALDH1A1 2381/4885TSHR 1711/4885 |
| US-20160318852-A1 | BENZAMIDES AND NICOTINAMIDES AS SYK MODULATORS | SYK, BTK, NADK | POLB 3714/4885ALDH1A1 1312/4885TSHR 4257/4885 |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, PSMB1, PSMB3 | POLB 729/4885ALDH1A1 3650/4885TSHR 2821/4885 |
| US-20170260230-A1 | COMPUNDS FOR ENZYME INHIBITION | ANPEP, PSMB1, CPN1 | POLB 440/4885ALDH1A1 3164/4885TSHR 2901/4885 |
| US-10669242-B2 | Clostridium difficile toxin inhibitors | GABRA5, GABRA1, GABBR2 | POLB 3866/4885ALDH1A1 1908/4885TSHR 1362/4885 |
| US-10150794-B2 | Compounds for enzyme inhibition | ANPEP, HPN, DNPEP | POLB 620/4885ALDH1A1 3041/4885TSHR 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.